Performance Evaluation of Combined Detection of Serum CEA,CYFRA21-1,CA125,and NSE in Patients with Lung Cancer by Fluorescence Flow Cytometry

Objective:To investigate the effect of combined detection of serum carcinoembryonic antigen(CEA),cytokeratin 19 fragment(CYFRA21-1),cancer antigen 125(CA125),and neuron-specific enolase(NSE)in patients with lung cancer by fluorescence flow cytometry.Methods:From August 2019 to July 2022,200 patients with lung cancer diagnosed by pathology in our hospital were retrospectively analyzed.2 mL venous blood was collected in a fasting state and centrifuged to separate the serum(containing human chorionic gonadotropin antibody[anti-hCG antibody],hepatitis B surface antibody[anti-HBs antibody],and CEA).Results:The sensitivities of CEA and CYFRA21-1 detected via enzyme-linked immunosorbent assay(ELISA)were 100%,and the detection limits were 0.5 ng/mL and 0.1 ng/mL,respectively;the sensitivities of CA125 and NSE detected via flow cytometry were 100%,and the detection limits were 10 U/mL and 2 ng/mL,respectively.Compared with ELISA,the sensitivities of CA125 and NSE detected via flow cytometry were higher.When the concentration of CEA was 10-40 ng/mL,the sensitivities of the three markers CYFRA21-1,CA125,and NSE showed no significant changes(P>0.05);when the concentration of CEA was 40-80 ng/mL,the sensitivity of CEA significantly decreased(P<0.01),but the sensitivities of the three markers CYFRA21-1,CA125,and NSE showed no significant changes(P>0.05);when the concentration of CEA was 80-200 ng/mL,the sensitivities of all four markers showed no significant changes(P>0.05).Conclusion:Compared with the double-antibody sandwich ELISA,fluorescence flow cytometry has certain advantages,including high sensitivity,good precision,short detection time,low sample usage,and low medical cost;thus,it is worthy of clinical promotion.

The Clinical Value of Detecting the Level of Exfoliated Cells in Pleural Effusion by Flow Cytometry in the Differential Diagnosis of Non-

Objective:To explore the value of flow cytometry(FCM)in detecting the level of exfoliated cells in pleural effusion in the differential diagnosis of non-small cell lung cancer and benign lung diseases.Methods:Clinical data of patients with non-small cell lung cancer who were hospitalized in Hebei hospital from June 2019 to March 2022 were collected.A total of 98 patients were included,and 63 patients with alveolar lung disease were screened during the same period,and the two groups of patients were analyzed.Results:Compared with alveolar lung disease group,FCM detection and analysis showed that the level of exfoliated cells in the pleural effusion of non-small cell lung cancer(NSCLC)patients was 99(3-969)/100,000,and patients with alveolar lung disease was 4(0~19)/100,000.Additionally,compared with the alveolar lung disease group,the level of exfoliated cells in the pleural effusion of patients with non-small cell lung cancer(NSCLC)was significantly increased(P<0.001).The diagnostic efficacy of FCM for detecting pleural fluid exfoliated cells in non-small cell lung cancer was assessed using ROC curves and using 95%CI(-11.1,-13.2)with a sensitivity of 0.75 and specificity of 0.94,and the diagnostic efficacy of FCM for detecting pleural fluid exfoliated cells in alveolar lung disease was assessed using 95%CI(-11.1,-13.2)with a sensitivity of 0.71 and specificity of 0.87.Conclusion:Flow cytometry has a wider range of clinical applications,simple operation,low cost,and high sensitivity,which makes it of great significance in disease diagnosis.

Expression of Hsp27 and Hsp70 in Lymphocytes and Plasma in Healthy Workers and Coal Miners with Lung Cancer

In coal mines, main occupational hazard is coal-mine dust, which can cause health problem including coal workers’ pneumoconiosis and lung cancer. Some heat shock proteins (Hsps) have been reported as an acute response to a wide variety of stressful stimuli. Whether Hsps protect against chronic environmental coal-mine dust over years is unknown. It is also interesting to know that whether the expression of Hsp27 and Hsp70 proteins as a marker for exposure is associated risk of lung cancer among coal miners. We investigated the association between levels of Hsp27 and Hsp70 expression in lymphocytes and plasma and levels of coal-mine dust exposure in workplace or risk of lung cancer in 42 cancer-free non-coal miners, 99 cancer-free coal miners and 51 coal miners with lung cancer in Taiyuan city in China. The results showed that plasma Hsp27 levels were increased in coal miners compared to non-coal miners (P<0.01). Except high cumulative coal-mine dust exposure (OR=13.62, 95%CI=6.05—30.69) and amount of smoking higher than 24 pack-year (OR=2.72, 95% CI=1.37—5.42), the elevated levels of plasma Hsp70 (OR=13.00, 95% CI=5.14—32.91) and plasma Hsp27 (OR=2.97, 95% CI=1.40—6.32) and decreased expression of Hsp70 in lymphocytes (OR=2.36, 95% CI=1.05—5.31) were associated with increased risk of lung cancer. These findings suggest that plasma Hsp27 may be a potential marker for coal-mine dust exposure. And the expression of Hsp27 and Hsp70 levels in plasma and lymphocytes may be used as biomarkers for lung cancer induced by occupational coal-mine dust exposure.

Factors influencing the presence of circulating differentiated thyroid cancer cells in the thyroidectomy perioperative period

Objective The aim of the study was to detect circulating differentiated thyroid cancer(DTC) micrometastasis and to investigate the factors influencing their presence in the perioperative thyroidectomy period. Methods DTC micrometastases in the peripheral blood were detected with flow cytometry,and patient clinical and pathological factors were analyzed in 327 DTC patients. Results Circulating blood micrometastases were present in the peripheral circulation at a higher rate 1 week postoperatively than preoperatively and at 4 weeks postoperatively(P < 0.05). The preoperative presence of circulating micrometastasis was associated with the size of the tumor and the presence of lymph node metastasis(P < 0.05),but was not related to the degree of tumor differentiation(P > 0.05). At 4 weeks postoperatively,the presence of circulating micrometastasis was not associated with tumor size or lymph node stage(P > 0.05),but was associated with poorly differentiated tumors(P < 0.05). Conclusion The presence of circulating DTC micrometastases correlates to tumor size,lymph node stage,and operative manipulation. The differentiation degree of the tumors were associated with the persistent presence of micrometastasis in the circulating blood.

HLA Class I Expressions on Peripheral Blood Mononuclear Cells in Colorectal Cancer Patients

Objective： To investigate the expression change of human leukocyte antigen （HLA） class I on human peripheral blood mononuclear ceils （PBMCs） at both mRNA and protein levels, and to evaluate its roles in the development of colorectal cancer （CRC）. Methods： In the present study, 50 patients with CRC, 35 patients with benign colorectal lesion and 42 healthy volunteers were enrolled. Expression levels of HLA class I mRNA and protein were determined using real-time quantitative reverse transcription PCR （RT-PCR） and flow cytometry analysis, respectively. Results： The expression levels of HLA class I mRNA and proteins were not influenced by age and gender. The relative ratios of HLA class I mRNA were 0.99±0.27 in healthy controls, 0.76±0.19 in benign patients, and 0.48±0.21 in CRC patients. Mean fluorescence intensities of HLA class I were 145.58±38.14 in healthy controls, 102.05±35.98 in benign patients and 87.44±34.01 in CRC patients. HLA class I on PBMCs was significantly down-regulated at both mRNA and protein levels in patients with stage III and IV CRC. CRC patients with lymph node metastasis also showed a decreased HLA class I expression at protein level. Conclusion： HLA class I expressions on PBMCs are associated with staging of CRC and lymph node metastasis. Monitoring the expression of HLA class I on PBMCs may provide useful information for diagnosis and metastasis judgement of CRC.

Detection of Circulating Tumor Cells in Patients with Breast, Prostate, Pancreatic, Colon and Melanoma Cancer: A Blinded Comparative Study Using Healthy Donors

Cancer is a diverse disease characterized by abnormal cell growth and the ability to invade or spread to other parts of the body. Because the yearly cancer rate is increasing, an important area for cancer researchers is to improve the ability to detect and treat cancer early. The current study analyzes the potential of flow cytometry to be used to detect circulating tumor cells (CTCs) in patients with various cancer types and stages. CTCs are cells that have detached from the primary tumor and entered the blood stream in the process of metastasizing to other organs. To determine the accuracy of flow cytometry in detecting CTCs, a comparative study was performed on healthy donors. In this study, blood samples from patients with breast, prostate, pancreatic, colon and skin cancer were analyzed and compared with healthy donors. The data were collected and analyzed statistically with receiver operating characteristic curve analysis. The results indicate that CTCs can be detected in over 83% of the cancer patients and therefore may be a promising method for diagnosing cancer.

The influence of autologous cytokine-induced killer cell treatment on the objective efficacy and safety of gefitinib in advanced non-small cell lung cancer

Objective The aim of the study was to observe the influence of autologous cytokine-induced killer cell(CIK) treatment on the objective efficacy and safety of gefitinib in advanced non-small cell lung cancer(NSCLC).Methods Sixty-six patients with NSCLC received gefitinib as second-line treatment. They were randomly divided into 2 groups, and informed consent forms were signed before grouping. Gefitinib was administrated to the control group, and autologous CIK treatment was added to the observation group. The objective treatment and adverse reactions were evaluated in both groups. Results The objective response rate(ORR) and the disease control rate(DCR) of the observation group were slightly higher than those of the control group, although no statistical differences were found between the 2 groups(P > 0.05). The incidences of diarrhea, fatigue, anorexia, oral ulcers, and myelosuppression in the observation group were much lower than those in the control group(P < 0.05). However, there were no statistical differences between the incidences of skin rash, and liver and kidney toxicities(P > 0.05). Conclusion Autologous CIK in combination with gefitinib is effective as second-line treatment for advanced NSCLC, and can significantly reduce adverse reactions and improve the objective efficacy.

The Inhibiting Effects and It's Molecular Mecanisms of the Fungi of Huai Er's on Human Large Cell Lung Cancer Cell Line L9981

Background and Objective Lung cancer, which threatens human’s health and life, is the malignant tumor with the most rapid increase of morbidity. Although recent years the basic

肿瘤特异性个体化多靶点DC-CIK治疗晚期非小细胞肺癌的临床疗效与安全性

目的:评价肿瘤特异性个体化多靶点树突状细胞-细胞因子诱导的杀伤细胞(DC-CIK)治疗晚期非小细胞肺癌(NSCLC)患者的临床疗效和安全性。方法:回顾性分析2019年10月1日至2022年10月31日东部战区总医院生物治疗科行肿瘤特异性个体化多靶点DC-CIK治疗晚期NSCLC患者的临床资料。统计NSCLC患者的临床疗效和不良反应,分析治疗前后血清中肿瘤标志物的变化,FCM检测患者治疗前后的淋巴细胞亚群和各种细胞因子的表达情况,用质谱仪检测治疗前后靶点的变化。结果:共入组52例晚期NSCLC患者,其中女性21例、男性31例;年龄32~71岁,平均年龄(50.97±10.72)岁,中位年龄47.5岁。经DC-CIK治疗后,CR 0例,PR 0例,SD 27例,PD 25例。与治疗前比较,DC-CIK治疗后:(1)CEA和CYFRA21-1水平无显著改变,CA125水平显著低于治疗前(P<0.01);(2)治疗后患者淋巴细胞亚群无显著变化;(3)治疗后患者外周血IL-2、IL-4、IFN-γ和TNF-α水平显著升高(均P<0.01),IL-6、IL-10及IL-17水平无明显变化(;4)治疗后靶点数下降明显。DC-CIK治疗过程中无严重不良反应发生。结论:晚期NSCLC患者行肿瘤特异性个体化多靶点自体DC-CIK治疗是安全的,能使患者产生抗肿瘤免疫反应并得到一定的临床获益。

DC-CIK联合化疗治疗晚期非小细胞肺癌的临床疗效

目的：研究DC—CIK联合化疗治疗晚期非小细胞肺癌的疗效及安全性。方法：选取2008年8月至2010年1月就诊于山西省肿瘤医院的50例Ⅲ～Ⅳ晚期非小细胞肺癌患者，采用DC—CIK联合化疗[多西他赛（docetaxel）＋顺铂（cisplatin）]为联合治疗组；选取临床资料相近的同期进行单纯化疗（多西他赛＋顺铂）的50例Ⅲ～Ⅳ晚期非小细胞肺癌患者为单纯化疗组，比较两组患者治疗后的免疫功能、近期疗效、1年生存率、生活质量，并观察DC—CIK细胞治疗的安全性。结果：成功培养患者的DC—CIK细胞，其中的CD3^＋CD8^＋、CD3^＋CD56^＋细胞比例较培养前显著提高（P〈0．05）。联合治疗组患者治疗后外周血各T细胞亚群均无明显变化，IFN．1水平显著升高（P〈0．05）；单纯化疗组患者治疗后外周血CD3^＋CD4^＋、CD3^＋CD8^＋、CD3-CD56^＋细胞比例下降（P〈0．05），IL-2、TNF-α水平明显降低（P〈0．05）。联合治疗组患者的DCR为78．0％，显著高于单纯化疗组的56．0％（P〈0．05）；联合治疗组患者1年生存率为50．0％，与单纯化疗组44．0％的差别无统计学意义（P〉0．05）。联合治疗组患者的不良反应（包括骨髓抑制、恶心呕吐、周围神经毒性）明显轻于单纯化疗组（P〈0．05），联合治疗组患者治疗后体力、食欲较单纯化疗组改善明显。结论：与单纯化疗相比，DC—CIK联合化疗治疗晚期非小细胞肺癌安全、有效，可以提高缓解率，延长生存期，改善患者的生活质量。

DC+CIK联合化疗治疗晚期非小细胞肺癌的临床疗效评价

目的:评价DC+CIK联合常规化疗治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法:选择70例晚期NSCLC患者进行研究,采用DC+CIK与常规化疗间隔进行的方案(生物治疗联合化疗组),对其进行生存分析;同时,对生物治疗联合化疗组、单纯常规化疗组同期配对NSCLC患者各61例,比较生物治疗联合化疗组与常规化疗对照组患者的生存率。结果:生物治疗联合常规化疗组患者预期1、2、3年生存率分别为59.6%、29.6%、21.80。生物治疗联合化疗组和单纯常规化疗组比较1年生存率分别为57.2%和37.3%,2年生存率分别为27.0%和10.1%(P<0.05)。结论:临床研究证实了DC+CIK联合常规化疗能够延长晚期NSCLC患者的生存期,提高患者的生存率和生活质量。

人外周血Vα24 NKT细胞和CD3^+CD56^+CIK细胞生物学特性的比较研究

目的进一步认识Vα24 NKT细胞和CIK细胞在生物学特性的差异。方法从人外周血单个核细胞扩增NKT细胞和CIK细胞;经免疫磁珠纯化获得高纯度的TCRVα24+NKT细胞和CD3+CD56+CIK细胞。运用流式细胞术测定纯化后的NKT细胞和CIK细胞的表型、细胞因子和细胞坏死相关因子的表达情况,并用DIOC18染色及流式细胞术测定纯化后的NKT细胞和CIK细胞的细胞杀伤活性。结果经纯化TCRVα24+Vβ11+NKT细胞和CD3+CD56+CIK细胞的纯度均达到>90%;纯化后的Vα24 NKT细胞多数为CD4+和DN NKT细胞,高表达TCRVα24、Vβ11、CD3、CD161,低表达CD56;而纯化后的CIK细胞则以CD8+T细胞为主,高表达CD3、CD56,低表达CD161,几乎不表达TCRVα24和Vβ11。在抗原刺激下,CD3+CD56+CIK细胞的IFN-γ、TNF-α、Perforin、FasL、TRAIL表达水平均高于NKT细胞,但CD3+CD56+CIK细胞几乎不分泌IL-4,而NKT细胞则分泌高水平的IL-4;CD3+CD56+CIK细胞对肿瘤细胞株K562、U937、Jurkat的杀伤率均远远高于NKT细胞。结论TCRVα24+NKT细胞和CD3+CD56+CIK细胞是两类完全不同的细胞群,在抗肿瘤免疫和免疫调节中可能起着不同的作用。

肺癌细胞中NKG2D配体MICA及ULBP高表达及其在CIK介导的肿瘤细胞杀伤中的作用

目的:探索肺癌细胞中NKG2D配体的表达量及其与CIK细胞介导的肿瘤细胞毒性的关系。方法:在肺癌组织、癌旁组织及肺癌细胞株中用实时荧光定量PCR及蛋白质免疫印迹法检测NKG2D配体的表达量。应用流式细胞仪检测肿瘤细胞株A549和QG56表面NKG2D配体的表达情况。体外分离培养CIK细胞,比较NKG2D单克隆抗体预处理CIK细胞和无NKG2D单克隆抗体预处理CIK细胞介导的肿瘤细胞毒性。结果:NKG2D在肺癌组织及肺癌细胞株中高表达。CIK细胞对肺癌细胞株A549表现出较强的细胞毒性,但用NKG2D单克隆抗体预处理CIK细胞后可显著降低这种作用(P<0.05)。结论:NKG2D配体在肺癌组织和肺癌细胞株中高表达。对于CIK细胞介导的肺癌细胞杀伤作用,NKG2D与其配体的相互作用至关重要。

中晚期非小细胞肺癌同步放化疗联合DC-CIK细胞生物治疗的疗效观察

目的:通过对同步放化疗联合DC-CIK细胞生物疗法治疗中晚期非小细胞肺癌的临床疗效进行观察,了解该治疗方法在中晚期非小细胞肺癌治疗中的意义及价值。方法:将我院收治的90例患者随机分为单纯同步放化疗组、同步放化疗交替DC-CIK免疫治疗组、同步放化疗序贯DC-CIK免疫治疗组,分别给予相应治疗,观察患者的治疗疗效、免疫水平以及治疗导致的不良反应情况。结果:同步放化疗交替DC-CIK细胞免疫治疗能够提高中晚期非小细胞肺癌患者的完全缓解率、部分缓解率以及临床有效率,但差异不具有统计学意义。同步放化疗交替DC-CIK细胞免疫治疗以及同步放化疗序贯DC-CIK细胞免疫治疗均能够提高中晚期非小细胞肺癌患者的免疫水平。此外,同步放化疗交替DC-CIK细胞免疫治疗能够降低单纯同步放化疗导致的粒细胞水平降低及放射性肺炎的发生率,但可能导致患者发热的发生。结论:同步放化疗交替DC-CIK细胞免疫治疗在中晚期非小细胞肺癌的治疗中较单纯同步放化疗具有优势。

CIK细胞用于中晚期非小细胞肺癌一线维持治疗的临床观察

目的探讨自体细胞因子诱导的杀伤（CIK）细胞免疫治疗在中晚期非小细胞肺癌（NSCLC）一线维持治疗中的疗效及安全性。方法选取本院2009年6月至2011年3月接受一线治疗且疗效评价稳定（SD）或以上的NSCLC患者112例,随机分为治疗组（n=56）和对照组（n=56）。在接受一线化疗方案原药或减药的维持化疗基础上,治疗组加用CIK细胞免疫治疗,检测CIK细胞治疗前后外周血T细胞亚群的变化;根据药物毒副反应判定标准NCI-CTC 4.0,观察两组患者的毒副反应情况并随访远期生存。结果 CIK治疗后较治疗前T细胞亚群状态改善,未见3~4级不良反应。治疗组的中位无进展生存期（PFS）为8.6个月,高于对照组的7.5个月（P〈0.05）,中位生存时间（OS）分别为19.2个月和18.6个月,差异无统计学意义（P〉0.05）;治疗组中一线疗效≥50%PR-CR者（靶病灶最大径之和缩小50%~100%）的中位PFS为11.5个月,高于疗效〈50%PR-SD者（靶病灶最大径之和缩小0~50%）的7.9个月（P〈0.05）,但中位OS的差异无统计学意义（P〉0.05）;对照组中一线疗效≥50%PR-CR者和疗效〈50%PR-SD者中位PFS及OS的差异均无统计学意义（P〉0.05）;一线疗效≥50%PR-CR者中,治疗组的中位PFS为11.5个月,亦高于对照组的8.8个月（P〈0.05）,但中位OS的差异无统计学意义（P〉0.05）。结论 CIK细胞免疫治疗在中晚期NSCLC维持治疗中,可以改善患者免疫功能,提高自身抗肿瘤能力,延长PFS,而且具有良好的安全性,可提高NSCLC维持治疗的疗效。

氩氦刀冷冻联合CIK细胞免疫治疗非小细胞肺癌的临床疗效

目的探讨氩氦刀冷冻联合CIK细胞免疫治疗非小细胞肺癌的疗效及对免疫功能影响。方法将该院收治的90例非小细胞肺癌患者随机分为单纯氩氦刀组(A组)30例,单纯CIK治疗组(B组)30例,氩氦刀联合CIK治疗组(C组)30例,观察其临床疗效、生活质量变化及免疫功能等相关指标。结果 A组与C组对非小细胞肺癌疗效相当,差异不具有显著性(P>0.05),但疗效均显著优于B组(P<0.05)。治疗后三组患者的KPS评分较治疗前均有明显的增加(P<0.05),C组的KPS评分明显高于其他两组(均P<0.05)。三组淋巴细胞亚群检查显示,C组的CD3+、CD4+、CD8+、CD4+/CD8+细胞也较A组和B组有明显改善(均P<0.05)。B组患者出现发热等不良反应发生率明显低于其他两组(均P<0.05)。结论氩氦刀联合CIK细胞治疗非小细胞肺癌具有协同作用,可以提高对肿瘤的杀伤效果,且能显著增强患者的免疫功能。

DC-CIK细胞联合常规化疗治疗晚期非小细胞肺癌的临床有效性与安全性分析

目的分析DC-CIK细胞联合常规化疗治疗晚期非小细胞肺癌（NSCLC）的临床有效性与安全性。方法选取2010年1月至2013年10月肿瘤科收治的晚期NSCLC患者81例,依据治疗方式不同,将行NP化疗联合DCCIK细胞治疗者设为观察组（40例）,行NP化疗者设为对照组（41例）。观察并记录患者的治疗效果（实体瘤的疗效评价标准）、体力状态（Karnofsky评分法）、免疫功能变化、血常规、肝肾功能、不良反应、生存等情况。结果观察组患者的总有效率为37.50%,对照组为29.27%,2组比较差异无统计学意义（χ2=1.468,P〉0.05）;疾病控制率、体力状态总提高率观察组为87.50%、90.00%高于对照组的75.61%、73.17%（χ2=5.374、10.957,P〈0.05）。截止到随访日期,观察组40例患者,死亡30例,存活10例,其中位无瘤生存期7.5个月（95%CI为5.16-8.95）,中位生存期14.5个月（95%CI为10.05-17.95）;对照组41例患者,死亡35例,6例存活,其中位无瘤生存期4.5个月（95%CI为3.17-6.92）,中位生存期11.5个月（95%CI为9.11-14.87）;Log-rank检验显示,观察组患者中位无瘤生存期长于对照组（χ2=6.557,P〈0.05）;观察组患者中位生存时间长于对照组,但差异无统计学意义（χ2=1.384,P〉0.05）。2组患者治疗前外周血T淋巴细胞CD＋3、CD＋8、CD＋56阳性百分比接近（t=1.395,P〉0.05;t=1.864,P〉0.05;t=1.647,P〉0.05）;观察组患者治疗后外周血T淋巴细胞CD＋3、CD＋8、CD＋56阳性百分比较治疗前升高（t=5.627,P〈0.05;t=5.974,P〈0.05;t=6.057,P〈0.05）;对照组治疗后外周血T淋巴细胞CD＋3、CD＋8、CD＋56阳性百分比较治疗前降低（t=1.412,P〉0.05;t=1.967,P〉0.05;t=1.754,P〉0.05）;治疗后,观察组患者外周血T淋巴细胞CD＋3、CD＋8、CD＋56阳性百分比显著高于对照组（t=12.367,P〈0.05;t=13.574,P〈0.05;t=10.324,P〈0.05）。观察组患者的发热率高于对照组χ2=6.549,P=0.032）;2组患者白细胞降低、血小板降低、脱发、消化道反应、肝功能损害、肾功能损害等不良反应发生率比较差异均无统计学意义（χ2=2.014,P〉0.05;χ2=1.247,P〉0.05;χ2=1.954,P〉0.05;χ2=1.358,P〉0.05;χ2=1.657,P〉0.05;χ2=1.028,P〉0.05）;2组患者不良反应轻微,给予对症处理后均得到控制。结论 DC-CIK细胞联合常规化疗是晚期非小细胞肺癌患者安全有效的治疗方式,可考虑推广应用。

DC-CIK细胞免疫治疗联合化疗对卵巢癌免疫功能的影响

目的 探讨细胞因子诱导的杀伤（cytokine-induced killer,CIK）细胞、树突状细胞（dendritic cells,DC）免疫治疗联合化疗对晚期卵巢癌患者外周血淋巴细胞亚群的影响,并评估其治疗效果. 方法 选取2011-09～2013-08就诊于新乡市中心医院的62例卵巢上皮性恶性肿瘤患者,其中30例患者采用DC-CIK联合化疗[紫杉醇（taxel）＋卡铂（cisplatin）]为联合治疗组;选取同期进行单纯化疗的32例患者为单纯化疗组.3周为1个周期,3周期后评价疗效.治疗结束1周后采用流式细胞仪检测外周血CD3＋、CD3＋ CD4＋、CD4＋/CD8＋、CD4＋ CD25＋T调节性T细胞、NK细胞的变化. 结果 每位患者治疗3个周期后,联合治疗组患者外周血CD3＋、CD3＋ CD4＋、CD4＋/CD8＋、NK水平明显高于单纯化疗组（P＜0.05）.联合治疗组患者的客观缓解率为85.7％,显著高于单纯化疗组的56.5％ （P ＜0.05）.联合治疗组患者的不良反应（包括骨髓抑制、肝功能损害）明显轻于单纯化疗组（P＜0.05）,联合治疗组患者治疗后体力状况评分较单纯化疗组改善明显. 结论 DC-CIK细胞免疫治疗联合化疗能提高卵巢癌患者的细胞免疫功能,且安全有效.

DC-CIK生物免疫疗法联合单药化疗治疗老年晚期非小细胞肺癌的回顾性研究

目的探讨树突状细胞共培养细胞因子诱导的杀伤细胞(DC-CIK)联合单药化学治疗(简称化疗),治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效和安全性。方法回顾性分析106例具有完整随访资料的老年晚期非小细胞肺癌患者,通过比较单药化疗组(A组)、DC-CIK联合单药化疗组(B组)、DC-CIK治疗组(C组)、最佳支持治疗组(D组)间的客观缓解率(ORR)、疾病控制率(DCR)、疾病进展时间(TTP)及严重不良事件发生率(SSR),评价其临床疗效和安全性。结果 4组患者ORR比较有显著性差异,其中A组、B组及C组均显著高于D组(P<0.05),但3组间未见明显差异(P>0.05)。4组患者DCR有显著性差异,其中B组显著高于其他3组(P<0.05)。4组患者TTP比较差异明显(P<0.05),其中B组较其他3组明显延长(P<0.05)。D组SSR明显低于其余3组,而B组SSR高于C组,但显著低于A组,差异均有统计学意义(P<0.05)。结论 DC-CIK生物免疫疗法联合单药化疗能安全、有效地延长老年晚期非小细胞肺癌患者的疾病进展时间。

DC-CIK联合化疗治疗中晚期非小细胞肺癌的临床观察

目的:探讨DC-CIK细胞在中晚期非小细胞肺癌(NSCLC)患者中的临床治疗效果。方法:80例中晚期NSCLC患者按治疗方法分为化疗组(A组)和DC-CIK联合化疗组(B组),各40例;A组采用常规化疗方案铂类联合盐酸吉西他滨4个疗程;B组同时实施DCCIK细胞治疗。4个月时比较两组治疗效果及毒副作用。随访1年时比较无疾病进展期和死亡率。结果:B组CR8例,PR9例,SD17例,PD6例,A组CR6例,PR7例,SD15例,PD12例。B组临床有效率、临床获益率显著高于A组(P<0.05);两组间骨髓抑制、肝肾功能损害无显著差异。B组胃肠道反应、疲乏乏力及食欲减退显著低于A组(P<0.05)。随访1年B组无疾病进展期(PFS)7.4月,A组PFS为6.1月(P<0.05)。两组间1年死亡率无显著差异。结论:NSCLC中晚期在放、化疗,靶向药物综合治疗的过程中尽早应用DCCIK,能够提高临床疗效,降低治疗毒副反应,提高机体免疫力,改善患者生存质量。